BA
PGNX

BlackRock Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

BlackRock Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$471K Buy
54,522
+17,688
+48% +$131K ﹤0.01% 2243
2016
Q3 		$233K Sell
36,834
-59,055
-62% -$357K ﹤0.01% 2602
2016
Q2 		$405K Buy
95,889
+1,941
+2% +$9.37K ﹤0.01% 2231
2016
Q1 		$410K Buy
93,948
+2,686
+3% +$12K ﹤0.01% 2187
2015
Q4 		$559K Sell
91,262
-17,777
-16% -$117K ﹤0.01% 2023
2015
Q3 		$624K Sell
109,039
-2,981
-3% -$22.9K ﹤0.01% 2027
2015
Q2 		$836K Buy
112,020
+67,054
+149% +$406K ﹤0.01% 1791
2015
Q1 		$269K Buy
44,966
+6,102
+16% +$38.4K ﹤0.01% 2509
2014
Q4 		$294K Sell
38,864
-3,381
-8% -$20.2K ﹤0.01% 2371
2014
Q3 		$219K Sell
42,245
-1,983
-4% -$9.88K ﹤0.01% 2554
2014
Q2 		$191K Sell
44,228
-6,711
-13% -$25.6K ﹤0.01% 2661
2014
Q1 		$208K Buy
50,939
+10,089
+25% +$51.6K ﹤0.01% 2618
2013
Q4 		$218K Buy
40,850
+3,505
+9% +$15.4K ﹤0.01% 2607
2013
Q3 		$187K Buy
37,345
+6,660
+22% +$36.1K ﹤0.01% 2599
2013
Q2 		$137K Buy
+30,685
New +$138K ﹤0.01% 2694

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's PGNX Position: Q4 2016 in Review

BlackRock Advisors increased its Progenics Pharmaceuticals Inc (PGNX) stake by 48% in Q4 2016, buying an estimated $131K and bringing the position to 54,522 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #2243.

BlackRock Advisors first reported a position in PGNX in Q2 2013 and has held it in 15 quarters since. The position peaked at $836K in Q2 2015. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • BlackRock Advisors held 54,522 shares of Progenics Pharmaceuticals Inc worth $471K as of Q4 2016.
  • BlackRock Advisors bought 17,688 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $131K.
  • Progenics Pharmaceuticals Inc made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2243 holding.
  • BlackRock Advisors first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Progenics Pharmaceuticals Inc position peaked at $836K in Q2 2015.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.